TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Medivation Inc (NASDAQ: MDVN) Investor Securities Class Action Lawsuit 03/09/2010

  • If you purchased shares of Medivation Inc (NASDAQ: MDVN), you might have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Medivation, Inc.
Security
NASDAQ: MDVN

Case Name
Medivation Shareholder Class Action Lawsuit 03/09/2010
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the Northern District of California

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Medivation, Inc..
Summary

March 7, 2014 - The U.S. Court of Appeals for the Ninth Circuit ordered the judgment of the district court is affirmed and the case is dismissed.
April 20, 2012 - The lead plaintiff filed a notice of appeal.

March 22, 2012 - The court granted the defendants' motion to dismiss and issued a judgment closing the case.

January 13, 2012 - The defendants filed a motion to dismiss.

November 28, 2011 - The lead plaintiff filed a third amended complaint.

November 2, 2011 - The lead plaintiff filed a second amended complaint.

August 18, 2011 - The court granted the defendants' motion to dismiss and granted lead plaintiff leave to file an amended complaint.

June 8, 2011 - The defendants filed a motion to dismiss.

May 9, 2011 - The lead plaintiff filed an amended consolidated complaint on behalf of investors who purchased Medivation Inc (NASDAQ: MDVN) common shares between September 21, 2006 and March 2, 2010. The lead plaintiff alleges that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between September 21, 2006 and March 2, 2010.

April 8, 2011 - The lead plaintiff and lead counsel were appointed and all cases were consolidated.

May 10, 2010 - Lead plaintiff motions were filed.

March 9, 2010 - An investors in shares of Medivation Inc (NASDAQ: MDVN) filed a lawsuit in the U.S. District Court for the Northern District of California against Medivation Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between July 17, 2008 and March 2, 2010.

According to the complaint, the plaintiff alleges that Medivation Inc and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing between July 17, 2008 and March 2, 2010 false and misleading statements regarding its drug Dimebon. Then, on March 3, 2010, before the market opened, defendants were forced to publicly disclose that Dimebon did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer’s disease, and as a result of this news, Medivation Inc’s stock (NASDAQ: MDVN) plummeted $27.15 per share to close at $13.10 per share on March 3, 2010 – a one-day decline of 67%, so the lawsuit. Shares of Medivation Inc (NASDAQ: MDVN) continued to decline from its 52weekHigh of $40.49 per share to $12.10 per share on Tuesday, March 09, 2010.

Medivation Inc, located in San Francisco, California, is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer’s disease, Huntington’s disease and castration-resistant prostate cancer.